NINIVAGGI DANIEL A 4

What Happened
Daniel A. Ninivaggi, a director of Indivior Pharmaceuticals, was granted 3,722 restricted stock units (RSUs) on January 26, 2026. The Form 4 reports the acquisition price as $0.00 and total reported value $0 (award/grant code A). This is a compensation award, not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-01-26; filing date: 2026-01-28 (Form 4 accession 0001257599-26-000006) — filing appears timely.
• Shares/units granted: 3,722 RSUs; reported price: $0.00; reported aggregate value: $0.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: RSUs represent a contingent right to one share each and vest on the day immediately preceding the issuer’s first annual meeting after the grant, subject to continued service.

Context
RSUs are a form of equity compensation that convert to actual shares only if and when they vest; they do not require the insider to pay cash at grant and do not indicate an immediate purchase or sale. Director awards are common as part of routine compensation and should be interpreted differently than open‑market purchases (which can signal a direct personal investment).